Analysis of Liquidity Ratios
Quarterly Data
Liquidity ratios measure the company ability to meet its short-term obligations.
Liquidity Ratios (Summary)
Allergan PLC, liquidity ratios (quarterly data)
Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).
| Liquidity ratio | Description | The company |
|---|---|---|
| Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Allergan PLC current ratio improved from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020. |
| Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Allergan PLC quick ratio improved from Q3 2019 to Q4 2019 but then deteriorated significantly from Q4 2019 to Q1 2020. |
| Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Allergan PLC cash ratio improved from Q3 2019 to Q4 2019 but then deteriorated significantly from Q4 2019 to Q1 2020. |
Current Ratio
Allergan PLC, current ratio calculation (quarterly data)
| Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
| Current assets | 7,474,100) | 11,126,700) | 9,593,600) | 8,572,800) | 6,289,300) | 6,475,400) | 5,740,200) | 6,103,700) | 6,393,300) | 11,376,700) | 10,112,800) | 10,433,200) | 13,700,700) | 17,857,900) | 31,723,900) | 8,755,200) | 10,091,500) | 8,615,400) | 16,658,700) | 10,486,900) | 11,017,200) | |||||||
| Current liabilities | 7,433,400) | 11,070,700) | 9,638,700) | 8,303,700) | 8,849,200) | 5,727,900) | 6,231,900) | 6,125,300) | 5,816,000) | 9,848,100) | 8,559,800) | 8,638,300) | 10,391,600) | 7,874,700) | 8,025,500) | 8,867,400) | 10,195,500) | 8,328,300) | 8,133,000) | 7,649,500) | 7,655,500) | |||||||
| Liquidity Ratio | ||||||||||||||||||||||||||||
| Current ratio1 | 1.01 | 1.01 | 1.00 | 1.03 | 0.71 | 1.13 | 0.92 | 1.00 | 1.10 | 1.16 | 1.18 | 1.21 | 1.32 | 2.27 | 3.95 | 0.99 | 0.99 | 1.03 | 2.05 | 1.37 | 1.44 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Current Ratio, Competitors2 | ||||||||||||||||||||||||||||
| AbbVie Inc. | 3.14 | 3.18 | 1.15 | 0.89 | 1.04 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 1.59 | 1.44 | 2.89 | 2.89 | 2.77 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 1.66 | 1.60 | 3.83 | 3.88 | 1.93 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 1.32 | 5.19 | 3.43 | 2.32 | 2.18 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 1.11 | 1.16 | 1.17 | 1.13 | 1.12 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 3.04 | 3.10 | 2.96 | 3.76 | 3.62 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 1.31 | 1.26 | 1.26 | 1.33 | 1.44 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 1.11 | 1.24 | 1.26 | 1.21 | 1.37 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 1.03 | 0.88 | 0.90 | 1.47 | 1.54 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 4.21 | 3.67 | 4.03 | 3.88 | 4.58 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 2.32 | 1.92 | 1.80 | 1.49 | 1.69 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 3.54 | 3.61 | 3.44 | 3.74 | 3.78 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).
1 Q1 2020 Calculation
Current ratio = Current assets ÷ Current liabilities
= 7,474,100 ÷ 7,433,400 = 1.01
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Allergan PLC current ratio improved from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020. |
Quick Ratio
Allergan PLC, quick ratio calculation (quarterly data)
| Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
| Cash and cash equivalents | 999,500) | 2,503,300) | 1,237,500) | 1,651,400) | 788,500) | 880,400) | 1,187,900) | 1,674,700) | 994,800) | 1,817,200) | 1,612,700) | 886,900) | 1,092,900) | 1,724,000) | 7,554,700) | 489,500) | 2,260,800) | 1,096,000) | 2,063,900) | 1,517,900) | 2,114,900) | |||||||
| Marketable securities | 1,618,800) | 3,411,600) | 3,318,400) | 322,300) | 995,200) | 1,026,900) | 22,000) | 21,500) | 1,037,400) | 4,632,100) | 3,829,100) | 4,939,000) | 7,858,200) | 11,501,500) | 19,837,600) | 17,100) | 13,000) | 9,300) | 7,000) | 8,500) | 16,000) | |||||||
| Accounts receivable, net of allowances for doubtful accounts and credit losses | 2,800,600) | 3,192,300) | 3,012,300) | 3,086,300) | 2,731,200) | 2,868,100) | 2,826,900) | 2,760,800) | 2,639,200) | 2,899,000) | 2,808,600) | 2,795,900) | 2,542,000) | 2,531,000) | 2,398,500) | 2,490,500) | 2,652,800) | 2,401,600) | 2,143,200) | 4,420,100) | 3,992,800) | |||||||
| Total quick assets | 5,418,900) | 9,107,200) | 7,568,200) | 5,060,000) | 4,514,900) | 4,775,400) | 4,036,800) | 4,457,000) | 4,671,400) | 9,348,300) | 8,250,400) | 8,621,800) | 11,493,100) | 15,756,500) | 29,790,800) | 2,997,100) | 4,926,600) | 3,506,900) | 4,214,100) | 5,946,500) | 6,123,700) | |||||||
| Current liabilities | 7,433,400) | 11,070,700) | 9,638,700) | 8,303,700) | 8,849,200) | 5,727,900) | 6,231,900) | 6,125,300) | 5,816,000) | 9,848,100) | 8,559,800) | 8,638,300) | 10,391,600) | 7,874,700) | 8,025,500) | 8,867,400) | 10,195,500) | 8,328,300) | 8,133,000) | 7,649,500) | 7,655,500) | |||||||
| Liquidity Ratio | ||||||||||||||||||||||||||||
| Quick ratio1 | 0.73 | 0.82 | 0.79 | 0.61 | 0.51 | 0.83 | 0.65 | 0.73 | 0.80 | 0.95 | 0.96 | 1.00 | 1.11 | 2.00 | 3.71 | 0.34 | 0.48 | 0.42 | 0.52 | 0.78 | 0.80 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Quick Ratio, Competitors2 | ||||||||||||||||||||||||||||
| AbbVie Inc. | 2.88 | 2.91 | 0.92 | 0.64 | 0.78 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 1.10 | 1.01 | 2.28 | 2.41 | 2.37 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 1.38 | 1.26 | 3.63 | 3.61 | 1.64 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 0.92 | 4.68 | 2.99 | 1.78 | 1.58 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 0.64 | 0.68 | 0.66 | 0.67 | 0.65 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 2.78 | 2.86 | 2.74 | 3.41 | 3.32 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 0.98 | 0.94 | 0.93 | 0.95 | 1.01 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 0.66 | 0.78 | 0.80 | 0.75 | 0.88 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 0.60 | 0.50 | 0.50 | 0.71 | 0.72 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 3.38 | 2.81 | 3.14 | 2.99 | 3.66 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 1.48 | 1.19 | 0.97 | 0.85 | 0.89 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 3.27 | 3.33 | 3.20 | 3.51 | 3.54 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).
1 Q1 2020 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 5,418,900 ÷ 7,433,400 = 0.73
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Allergan PLC quick ratio improved from Q3 2019 to Q4 2019 but then deteriorated significantly from Q4 2019 to Q1 2020. |
Cash Ratio
Allergan PLC, cash ratio calculation (quarterly data)
| Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
| Cash and cash equivalents | 999,500) | 2,503,300) | 1,237,500) | 1,651,400) | 788,500) | 880,400) | 1,187,900) | 1,674,700) | 994,800) | 1,817,200) | 1,612,700) | 886,900) | 1,092,900) | 1,724,000) | 7,554,700) | 489,500) | 2,260,800) | 1,096,000) | 2,063,900) | 1,517,900) | 2,114,900) | |||||||
| Marketable securities | 1,618,800) | 3,411,600) | 3,318,400) | 322,300) | 995,200) | 1,026,900) | 22,000) | 21,500) | 1,037,400) | 4,632,100) | 3,829,100) | 4,939,000) | 7,858,200) | 11,501,500) | 19,837,600) | 17,100) | 13,000) | 9,300) | 7,000) | 8,500) | 16,000) | |||||||
| Total cash assets | 2,618,300) | 5,914,900) | 4,555,900) | 1,973,700) | 1,783,700) | 1,907,300) | 1,209,900) | 1,696,200) | 2,032,200) | 6,449,300) | 5,441,800) | 5,825,900) | 8,951,100) | 13,225,500) | 27,392,300) | 506,600) | 2,273,800) | 1,105,300) | 2,070,900) | 1,526,400) | 2,130,900) | |||||||
| Current liabilities | 7,433,400) | 11,070,700) | 9,638,700) | 8,303,700) | 8,849,200) | 5,727,900) | 6,231,900) | 6,125,300) | 5,816,000) | 9,848,100) | 8,559,800) | 8,638,300) | 10,391,600) | 7,874,700) | 8,025,500) | 8,867,400) | 10,195,500) | 8,328,300) | 8,133,000) | 7,649,500) | 7,655,500) | |||||||
| Liquidity Ratio | ||||||||||||||||||||||||||||
| Cash ratio1 | 0.35 | 0.53 | 0.47 | 0.24 | 0.20 | 0.33 | 0.19 | 0.28 | 0.35 | 0.65 | 0.64 | 0.67 | 0.86 | 1.68 | 3.41 | 0.06 | 0.22 | 0.13 | 0.25 | 0.20 | 0.28 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Cash Ratio, Competitors2 | ||||||||||||||||||||||||||||
| AbbVie Inc. | 2.50 | 2.56 | 0.61 | 0.32 | 0.38 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 0.68 | 0.69 | 1.94 | 2.05 | 2.07 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 0.95 | 0.84 | 3.10 | 3.02 | 0.99 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 0.52 | 4.04 | 2.40 | 1.08 | 0.84 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 0.14 | 0.21 | 0.15 | 0.20 | 0.19 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 2.34 | 2.50 | 2.39 | 3.03 | 2.97 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 0.54 | 0.54 | 0.51 | 0.49 | 0.53 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 0.32 | 0.47 | 0.39 | 0.35 | 0.47 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 0.31 | 0.26 | 0.25 | 0.40 | 0.39 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 1.95 | 1.53 | 1.63 | 1.56 | 2.14 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 0.54 | 0.39 | 0.22 | 0.30 | 0.19 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 2.72 | 2.85 | 2.88 | 3.14 | 3.14 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).
1 Q1 2020 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 2,618,300 ÷ 7,433,400 = 0.35
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Allergan PLC cash ratio improved from Q3 2019 to Q4 2019 but then deteriorated significantly from Q4 2019 to Q1 2020. |